trial · primary record
Placebo
Chronic Kidney Disease
| Phase | Phase 3 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 555 |
| Primary completion | 2026-05-07 |
| Primary endpoint | Estimated Percentage of Participants Who Experienced Major Adverse Kidney Events (MAKE, Based on Serum Cystatin C [sCysC)] at Day 90 Post-CPB (MAKE90) |
| Registry ID | NCT05746559 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:36.107Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05746559
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Placebo · compound